Trial site

Dunedin Hospital

Dunedin, 9054, New ZealandNot linked to an institution yet

25running trials
12closed trials

The trials here

What the 37 trials at this site are about, from their registry records.

Conditions: Chronic kidney disease4 trials
Chronic lymphocytic leukaemia4 trials
Crohn's disease4 trials
Heart failure4 trials
Ulcerative colitis4 trials
COPD3 trials
Idiopathic pulmonary fibrosis3 trials
Primary biliary cholangitis2 trials
Acute myeloid leukaemia1 trial
Aortic stenosis1 trial
Childhood cancers1 trial
Chronic myeloid leukaemia1 trial
and 16 more
Phase: Phase 319 trials
Phase 29 trials
Phase 2/33 trials
Status: Active, not recruiting19 trials
Completed9 trials
Recruiting6 trials
Terminated2 trials
Withdrawn1 trial
Lead sponsor: Janssen Research & Development, LLC6 trials
Hoffmann-La Roche4 trials
BeOne Medicines3 trials
Boehringer Ingelheim3 trials
Alleviant Medical, Inc.2 trials
and 18 more

Running trials

Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source
Contact: Shirley Jones
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217· Phase 2· Avalyn Pharma Inc.· Source
Contact: Dr. Felix Woodhead, MB BChir,PhD
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533· Alleviant Medical, Inc.· Source
Contact: Gerard Wilkins (principal investigator)
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· Phase 2· Avalyn Pharma Inc.· Source
Active, not recruiting
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
NCT05883956· Phase 3· Otsuka Australia Pharmaceutical Pty Ltd· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769· Phase 3· Hoffmann-La Roche· Source
Recruiting
Alleviant ALLAY-HF Study
NCT05685303· Alleviant Medical, Inc.· Source
Contact: Gerry Wilkins, A/Prof (principal investigator)
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747· Elixir Medical Corporation· Source
Recruiting
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NCT04204915· University of Leicester· Source
Contact: Dr Sean Coffey
Active, not recruiting
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506· Phase 3· Gilead Sciences· Source
Active, not recruiting
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source
Active, not recruiting
Radiotherapy - Adjuvant Versus Early Salvage
NCT00860652· Trans Tasman Radiation Oncology Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Heart failure3 recruiting
Aortic stenosis1 recruiting
Chronic lymphocytic leukaemia1 recruiting
High blood pressure1 recruiting
Type 1 diabetes1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Completed
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660· Phase 2· Boehringer Ingelheim· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Terminated
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822· Phase 2· Incyte Corporation· Source
Completed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· Phase 3· Hoffmann-La Roche· Source
Completed
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source
Completed
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
NCT04435626· Phase 3· Bayer· Source
Completed
Preventing Adverse Cardiac Events in COPD
NCT03917914· Phase 3· The George Institute· Source
Recruiting
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
NCT03573089· The University of Queensland· Source
Contact: Ron Wald
Completed
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085· Phase 3· Shire· Source
Completed
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source
Completed
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942· Phase 3· Hoffmann-La Roche· Source
Recruiting
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02582697· Phase 3· University of Sydney· Source
Contact: P3BEP Trial Coordinator

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error